Susan Morse
FDA approved drug Exondys 51 made by Sarepta Therapeutics to treat Duchenne muscular dystrophy.
The new CMS model allows insurers to design specific benefits to enrollees with a combination of chronic conditions.
Deal will be funded with available cash, and is due to close by first quarter 2017, company says.
The terms of the transaction, which is expected to close in early 2017, were not disclosed.
Grants will support the creation of programs enhancing primary care, mental health care, specialty care and other services in VA clinics.
Prescription drug model meant to avoid adverse risk of medications, lower costs.
The first phase addresses the effect the $54 billion deal would have on the national health insurance market.
The money will allow the Greater Flint Health Coalition to do outreach and enroll uninsured children so families can access available services.
The plan is part of the insurer's goal to increase the number of payments going to providers who practice value-based care from the current 40 percent to 75 percent by 2020.
The model will run for five years starting Jan. 1, 2017, in Arizona, Indiana, Iowa, Massachusetts, Oregon, Pennsylvania and Tennessee.